ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,607Medicare Part D Prescriptions Filled, Including Refills

Rank: 76 out of 1269

$443K Total Retail Price of All Prescriptions

Rank: 194 out of 1269

361 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
30% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 361 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

14% of this provider’s 361 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 8,017 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$46 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
FUROSEMIDE 414 344 1 5
AMLODIPINE BESYLATE 385 370 2 2
METOPROLOL TARTRATE 317 283 3 6
LEVOTHYROXINE SODIUM 289 272 4 4
LISINOPRIL 282 249 5 1
METFORMIN HCL 260 215 6 9
SIMVASTATIN 249 217 7 3
ATENOLOL 247 219 8 14
FENOFIBRATE 212 174 9 115
PRAVASTATIN SODIUM 205 183 10 11
OMEPRAZOLE 185 142 11 8
FAMOTIDINE 183 169 12 85
HYDROCODONE-ACETAMINOPHEN 164 121 S3 13 20
ISOSORBIDE MONONITRATE ER 161 151 14 63
WARFARIN SODIUM 153 147 15 12
LOSARTAN POTASSIUM 148 118 16 15
GABAPENTIN 129 85 17 17
ATORVASTATIN CALCIUM 122 105 18 7
DIOVAN 110 110 19 35
METOPROLOL SUCCINATE 108 93 20 13
ALLOPURINOL 106 89 21 49
DOXAZOSIN MESYLATE 106 106 21 117
DIGOXIN 100 95 23 62
HYDROCHLOROTHIAZIDE 100 100 23 10
TAMSULOSIN HCL 94 68 25 31
CRESTOR 92 90 26 25
POTASSIUM CHLORIDE 91 85 27 26
GLIPIZIDE ER 91 91 27 102
RANITIDINE HCL 90 84 29 27
FLUOXETINE HCL 84 59 30 83
LOVASTATIN 79 72 31 30
CLOPIDOGREL 78 78 32 32
GLIPIZIDE XL 77 55 33 125
ENALAPRIL MALEATE 73 73 34 79
NAMENDA 72 72 35 38
PREDNISONE 69 50 36 45
PLAVIX 67 67 37 47
GLIPIZIDE 65 65 38 37
LISINOPRIL-HYDROCHLOROTHIAZIDE 63 35 39 33
SERTRALINE HCL 59 42 40 23
RAMIPRIL 55 52 41 96
DONEPEZIL HCL 55 55 41 22
NITROGLYCERIN PATCH 54 54 43 114
PANTOPRAZOLE SODIUM 53 43 44 18
SPIRIVA 52 41 45 64
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 4, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.